Valuation: Intervacc AB

Market Cap 446M 46.2M 40.43M 37.31M 34.44M 65.36M 4.41B 66.41M 175M 2.17B 173M 170M 7.52B P/E 2026 *
-5.95x
P/E 2027 * -5.95x
Enterprise Value 353M 36.56M 32M 29.53M 27.26M 51.72M 3.49B 52.56M 138M 1.72B 137M 134M 5.95B EV / Sales 2026 *
19.9x
EV / Sales 2027 * 12.7x
Free-Float
80.66%
Yield 2026 *
-
Yield 2027 * -
1 day+0.62%
1 week-1.65%
Current month+0.31%
1 month+2.67%
3 months+55.90%
6 months+43.74%
Current year+41.56%
1 week 1.28
Extreme 1.28
1.35
1 month 1.25
Extreme 1.252
1.38
Current year 0.57
Extreme 0.572
1.46
1 year 0.57
Extreme 0.572
1.46
3 years 0.57
Extreme 0.572
10.46
5 years 0.57
Extreme 0.572
84
10 years 0.57
Extreme 0.572
95.5
Manager TitleAgeSince
Chief Executive Officer 70 04/02/2026
Director of Finance/CFO - 05/02/2020
Chief Tech/Sci/R&D Officer - 10/06/2020
Director TitleAgeSince
Director/Board Member 68 31/12/2024
Director/Board Member 72 31/12/2023
Director/Board Member 71 31/12/2022
Date Insider Type Main position Quantity % Market Cap.
22/02/25Free

Chief Financial Officer

929,208 1.2269%
16/02/25Sell

Chief Executive Officer

278,820 0.3681%
16/02/25Buy

Chief Executive Officer

135,000 0.1783%
Change 5-day change 1-year change 3-year change Capi.($)
+0.62%-1.65%+29.50%-72.55% 45.86M
-4.14%-8.06%+57.35%+117.24% 56.98B
+1.84%-0.66%+75.79%+93.87% 53.58B
-2.24%+3.59%+19.60%+466.72% 25.63B
-1.60%-6.21%-19.69%-14.84% 23.51B
+2.43%+1.06%+47.70%-0.11% 19.43B
-3.19%0.00%+33.99%-26.87% 18.12B
-6.84%+2.18%+195.12%+357.18% 16.46B
+8.74%+3.51%+53.81% - 14.13B
-1.05%+1.16%+25.08%+196.28% 14.35B
Average -0.54%+0.99%+51.83%+124.10% 24.23B
Weighted average by Cap. -1.02%+0.29%+54.67%+138.20%

Financials

2026 *2027 *
Net sales 17.7M 1.83M 1.61M 1.48M 1.37M 2.59M 175M 2.64M 6.94M 86.09M 6.89M 6.74M 299M 30.05M 3.11M 2.73M 2.52M 2.32M 4.41M 297M 4.48M 11.78M 146M 11.69M 11.44M 507M
Net income -80.8M -8.37M -7.33M -6.76M -6.24M -11.85M -799M -12.04M -31.67M -393M -31.44M -30.75M -1.36B -83.65M -8.67M -7.59M -7M -6.46M -12.26M -827M -12.46M -32.79M -407M -32.54M -31.84M -1.41B
Net Debt -93M -9.64M -8.44M -7.78M -7.19M -13.63M -919M -13.86M -36.45M -452M -36.18M -35.4M -1.57B -63M -6.53M -5.71M -5.27M -4.87M -9.24M -623M -9.39M -24.69M -306M -24.51M -23.98M -1.06B
Logo Intervacc AB
Intervacc AB is a Sweden-based biotechnology company. It develops vaccines based on recombinant proteins for animal health care. The Company’s candidate vaccine against strangles Strangvac consists of soluble recombinant proteins and devoids any living infectious agent. The Company operates through two subsidiaries: Nord Vacc Lakemedel AB and Mybac-Vettech AB. Nord Vacc Lakemedel AB markets and distributes veterinary vaccines, pharmaceuticals and vitamins on European market. It offers assortment of fur animal vaccines, the Febrivac range, as well as swine vaccines for Swedish and Danish markets. Mybac-Vettech AB is a technology platform that focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses.
Employees
16
Date Price Change Volume
10/07/26 SEK 1.308 +0.62% 124,005
09/07/26 SEK 1.300 0.00% 255,197
08/07/26 SEK 1.300 -0.76% 207,533
07/07/26 SEK 1.310 +0.77% 61,911
06/07/26 SEK 1.300 -2.26% 412,632

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IVACC Stock